All relevant data are within the paper.

Introduction {#sec005}
============

Tuberculosis (TB) is among the top ten causes of death and the leading cause of a single infectious agent worldwide \[[@pone.0232426.ref001]\]. Even though TB is a global problem, it mainly affects sub-Saharan African countries where the burden of *Human Immunodeficiency Virus (HIV)* is high \[[@pone.0232426.ref002]\]. There is a strong synergy between TB and *HIV* infection in resource-limited settings \[[@pone.0232426.ref001]\]. TB is the most frequently diagnosed opportunistic infections\[[@pone.0232426.ref003]\] and the leading killer among people living with *HIV* (PLHIV) \[[@pone.0232426.ref002]\]. The main reason for the resurgence of TB in Africa is the link between TB and *HIV* in addition to the lack of adequate economic and human resources \[[@pone.0232426.ref002]\]. TB facilitates the rapid progression of *HIV* disease \[[@pone.0232426.ref004]--[@pone.0232426.ref006]\]. In turn, *HIV* increases the lifetime risk of developing TB \[[@pone.0232426.ref007], [@pone.0232426.ref008]\]. In 2017, TB caused an estimated 300,000 deaths among *HIV* positive people. Ethiopia is among high TB, MDR/TB and TB/*HIV* burden countries with an estimated incidence rate of 164 TB cases per 100,000 population \[[@pone.0232426.ref001]\].

*Mycobacterium tuberculosis (MTB)* mainly affects the lung (pulmonary TB) but it can also affect other parts of the body (extrapulmonary TB) \[[@pone.0232426.ref001], [@pone.0232426.ref009]\]. The majority of TB cases estimated to be pulmonary TB, while in *HIV* positive individuals extrapulmonary tuberculosis (EPTB) has a significant proportion \[[@pone.0232426.ref001], [@pone.0232426.ref010]\]. Extrapulmonary tuberculosis is the isolated occurrence of TB in any part of the body other than the lungs. *MTB* may spread to any organ of the body through lymphatic or hematogenous dissemination and lay dormant for years at a particular site before causing disease \[[@pone.0232426.ref011], [@pone.0232426.ref012]\].

Even though EPTB is mostly common in *HIV* positives, it does not receive specific attention since it does not contribute significantly to the transmission of the disease. That is why national tuberculosis control programs are highly focused on pulmonary TB. Likewise, the majority of the previous studies done in Ethiopia mainly focused on the pulmonary type of TB. The information on the incidence of EPTB and its predictors among PLHIV is limited in the current setting. However, it is important to prevent and control EPTB related morbidity and mortality among *HIV* positive individuals. This study aimed to assess the incidence and predictors of EPTB among people living with *HIV* in selected public health facilities in Addis Ababa registered newly from 01 January 2013 up to 31 December 2013.

Methods {#sec006}
=======

Study setting {#sec007}
-------------

Retrospective data were collected from the patient's chart and registration books of seven anti-retroviral therapy (ART) clinics found in Addis Ababa, Ethiopia. Addis Ababa is the capital city of Ethiopia and the most populous city in the country. In the city, there are more than 123 ART clinics that provide treatment, care, and support to PLHIV. Among them, 18 ART centers in public health facilities had high patient flow.

Study design and period {#sec008}
-----------------------

An institution-based retrospective cohort study design was conducted. Data were collected in a period between July and August 2019.

Participants {#sec009}
------------

All people living with *HIV* free of EPTB and newly registered to ART clinics from 01 January 2013 to 31 December 2013 were included in the study and were followed retrospectively for five years up 31 December 2018. Individuals who didn't have baseline data and missed charts were excluded.

Sample size and sampling procedures {#sec010}
-----------------------------------

The sample size was calculated using double population proportion formula by using EpiInfo version 7.1 considering 95% confidence level, 80% power, 21.5% proportion among *HIV* positive patients with CD4 count\<200 cells/μl and 11% proportion among *HIV* positive patients with CD4 count\>500 cells/μl at time of *HIV* diagnosis \[[@pone.0232426.ref013]\]. With an assumption of equal sample size for exposed and non-exposed groups, a design effect of 1.5 and 5% for incomplete baseline data and missed charts a total sample size of 612 was determined.

A multi-stage sampling technique was followed. Eighteen health facilities that were identified to have a high patient flow were selected in the first stage purposely to get enough proportional samples by assuming a homogenous study population. Among these 18 ART clinics, seven were randomly selected using a simple random sampling technique. The selected ART clinics were; St. Paul's Hospital Millennium Medical College (SPHMMC), St. Peter Hospital, *Ras Desta Damtew* hospital, *Arada* Health Center, *Kirkose* Health Center, *Kolfe* Health Center, and *Addis Ketema* Health Center. A total of 612 patient records included in the data collection using a systematic random sampling method based on the proportion of registered patients in each facility.

Variables {#sec011}
---------

The outcome of the study was time to event of extrapulmonary tuberculosis in 100 person-years. The independent variables were socio-demographic characteristics, behavioral factors, and clinical factors. Socio-demographic characteristics include; age, sex, marital status, educational status, occupation, address, disclosure status, number of family members and homeless. Behavioral factors include; addiction to smoking, excessive alcohol use, *Khat* and substance use (*Shisha*). Clinical factors were; TB treatment history, functional status, WHO clinical stage, CD4 count, hemoglobin level, enrolled on ART, initial ART regimen type, isoniazid preventive treatment (IPT), co-trimoxazole preventive treatment (CPT), co-infection other than TB, body mass index, ART treatment adherence and ART regimen change.

Data collection and quality control {#sec012}
-----------------------------------

A structured data extraction form was used for data collection. The form was pre-tested on 5% of the total sample that was not included in the study. Nine data collectors collected the data from the patient's chart and registration books under the control of the principal investigator. Before data collection, training was given to data collectors to integrate the objective of the study, the method used and the contents of the data extraction form.

Operational definitions {#sec013}
-----------------------

Extrapulmonary tuberculosis operationalized as any bacteriological, histological or clinical diagnosis of EPTB during the follow-up period. PLHIV who developed EPTB during the follow-up period were considered as events, while those who transferred out, dead, dropped or alive on follow-up who did not develop EPTB were considered as censored. The time to develop EPTB was considered as EPTB free survival time.

Disclosure status: if there is anyone else who knows the *HIV* status of the patient it is operationalized as disclosed.

Any level of alcohol use and smoking was operationalized as a user.

Functional status is the condition of the patient at the time of enrollment in ART clinic categorized as to whether working (able to perform usual work), ambulatory (able to perform the activity of daily living) or bedridden functional status (not able to perform the activity of daily living).

IPT completion: taking the complete prophylaxis, such that a dose of 300mg/day isoniazid for six months.

ART interruption: any interruption of taking ART whether a single day or more was considered an interruption.

ART adherence: it is categorized as good when the patient misses three or fewer doses, fair when the patient misses between three and eight doses and poor when the patient missing more than eight doses per month.

Data processing and analysis {#sec014}
----------------------------

Data were entered using EpiInfo version 7.1 Software and exported to SPSS version 20.0 Software for analysis. Descriptive summary statistics used to characterize different variables. The event of interest was EPTB incidence. The incidence rate determined per 100 person-years (PYs). The EPTB incidence rate per 100 PYs of follow-up in each category was determined by dividing the number of EPTB in each category to the total person-years of the category and then multiplying by 100. The 95%CI for the incidence rate is determined using the formula 95%CI = e^ln\ incidence\ rate-Zα/^~2~\*^SE^, e^ln\ incidence\ rate\ +Zα/^~2~\*^SE^. Kaplan-Meier estimates and log-rank tests were used to describe time-to-event distributions and to compare time-to-event across the different categories respectively. Bi-variable and multivariable Cox proportional hazard models computed to identify the predictors of EPTB incidence. Variables with *P-value* \< 0.25 in the bi-variable analysis entered into the multivariable Cox-proportional model. A 95% CI of the hazard ratio computed, and those variables with *P-value* \< 0.05 in the multivariable analysis were considered statistically significant predictors of EPTB. Schoenfield residual test was used to assess Cox proportional hazard assumptions.

Ethical consideration and consent {#sec015}
---------------------------------

Ethical clearance was obtained from St. Paul's Hospital Millennium Medical College Ethical Review Committee, Addis Ababa City Administration Health Bureau and Saint Peter Specialized Hospital. Permission was obtained from all participating health facilities. Study unique identifier number was used in the entire data collection process, not to use patient identifiers. Since it is a retrospective study, obtaining consent to participate was not available.

Results {#sec016}
=======

Socio-demographic and behavioral characteristics {#sec017}
------------------------------------------------

Data were extracted from a total of 612 *HIV* positive patients\' charts. Among all, 46 excluded from the analysis due to not having a follow-up time. Therefore, the data extracted from 566 patient charts included in the analysis **([Fig 1](#pone.0232426.g001){ref-type="fig"}).** Majorities were females (385, 68%) and the mean age was 35.44 (±8.93) years. Married ones (260, 45.9%) contributed the largest number. More than half of the participants (305, 53.9%) were either not have formal education or completed primary school. Similarly, more than half (330, 58.5%) did not have work. Most of the participants resided in Addis Ababa (529, 93.5%). More than half (358, 63.3%) had an addiction at least to one substance (tobacco or alcohol or *khat* or *shisha*) (**[Table 1](#pone.0232426.t001){ref-type="table"}).**

![Flow chart, followed to assess the incidence of EPTB among *HIV* positive patients in Addis Ababa, Ethiopia, from 01 January 2013 up to 31 December 2018 (n = 612).](pone.0232426.g001){#pone.0232426.g001}

10.1371/journal.pone.0232426.t001

###### Socio-demographic and behavioral characteristics among *HIV* positive patients in Addis Ababa, Ethiopia, from 01 January 2013 up to 31 December 2018 (n = 566).

![](pone.0232426.t001){#pone.0232426.t001g}

  Characteristics            Number   Proportion
  -------------------------- -------- ------------
  Age group                           
  15--24                     38       6.7
  25--34                     230      40.6
  35--44                     205      36.2
  \>44                       93       16.4
  Sex                                 
  Female                     385      68
  Male                       181      32
  Marital status                      
  Single                     127      22.4
  Married                    260      45.9
  Separated/Divorced         114      20.1
  Widowed                    65       11.5
  Educational status                  
  No formal education        100      17.7
  Primary                    206      36.4
  Secondary                  195      34.5
  Tertiary                   65       11.5
  Employment status                   
  Yes                        236      41.7
  No                         330      58.3
  Address                             
  Addis Ababa                529      93.5
  Out of Addis Ababa         37       6.5
  Disclosure status                   
  Yes                        404      71.4
  No                         162      28.6
  Family size                         
  1--3                       334      59.0
  4--5                       165      29.2
  \>5                        67       11.8
  Homeless                            
  Yes                        4        0.7
  No                         562      99.3
  Tobacco smoking                     
  Yes                        278      49.1
  No                         288      50.9
  Alcohol addiction                   
  Yes                        312      55.1
  No                         254      44.9
  Taking Khat                         
  Yes                        296      52.3
  No                         270      47.7
  Taking Hard drugs/Shisha            
  Yes                        270      47.7
  No                         296      52.3

Clinical characteristics of study participants {#sec018}
----------------------------------------------

Around nine percent (53, 9.4%) of study participants had an experience of TB treatment history before they knew their *HIV* serostatus. Most (488, 86.2%) were found in a working baseline functional status during enrollment. Similarly, majorities categorized under WHO stage I or II (513, 91.2%) at baseline. The baseline CD4 count of 45.6% (258) of the study participants was \<200 cells/μl with a median count of 218 (IQR = 116--321) cells/μl. One third (182) had a BMI value of \<18.5 kg/m^2^ at the baseline with a mean value of 20.74 kg/m^2^ (±3.76) and the mean baseline Hgb value was 13.32 g/dl (±2.21). Majorities (84.1%, 476) were enrolled on HAART during the follow-up period. Less than half took a complete IPT (44.5%, 252), but majorities took CPT (84.1%, 476). Nearly half (46.8%, 265) were co-infected with different infections other than TB **([Table 2](#pone.0232426.t002){ref-type="table"}).**

10.1371/journal.pone.0232426.t002

###### Baseline and follow-up clinical characteristics among *HIV* positive patients in Addis Ababa, Ethiopia, from 01 January 2013 up to 31 December 2018 (n = 566).

![](pone.0232426.t002){#pone.0232426.t002g}

  Characteristics              Number   Proportion
  ---------------------------- -------- ------------
  Previous TB history                   
  Yes                          53       9.4
  No                           513      90.6
  Baseline functional status            
  Working                      488      86.2
  Ambulatory                   70       12.4
  Bedridden                    8        1.4
  Baseline WHO stage                    
  I /II                        513      91.2
  III /IV                      53       9.4
  Baseline CD4 count                    
  \<50                         47       8.3
  50--200                      211      37.3
  \>200                        308      54.4
  Baseline Hgb                          
  \<10g/dl                     51       9.0
  \>10g/dl                     515      91.0
  BMI                                   
  \<18.5                       182      32.2
  \>18.5                       384      67.8
  On HAART                              
  Yes                          476      84.1
  No                           90       15.9
  Initial treatment                     
  TDF/3TC/NVP                  14       2.94
  AZT/3TC/NVP                  56       11.76
  AZT/3TC/EFV                  39       8.19
  TDF/3TC/EFV                  367      77.10
  Took IPT Prophylaxis                  
  Yes                          252      44.5
  No                           314      55.5
  Took Co-trimoxazole                   
  Yes                          476      84.1
  No                           90       15.9
  Co-infection                          
  Yes                          265      46.8
  No                           301      53.2
  ART Treatment Interruption            
  Yes                          14       2.9
  No                           462      97.1
  ART adherence                         
  Good                         459      96.4
  Fair                         5        1.1
  Poor                         12       2.5
  ART regimen change                    
  Yes                          8        1.7
  No                           468      98.3

TB; Tuberculosis, WHO; World Health Organization, Hgb; hemoglobin, BMI; Body Mass Index, HAART; Highly Active Anti-Retroviral Treatment, IPT; Isoniazid Preventive Therapy, ART; Anti-Retroviral Therapy, TDF; Tenofovir, 3TC; Lamivudine, NVP; Nevirapine, AZT; Zidovudine, EFV; Efavirenz, co-infection; the presence of is any comorbidity or infection other than tuberculosis.

Incidence of extrapulmonary tuberculosis {#sec019}
----------------------------------------

A total of 566 *HIV* positive patients were followed for 2140.08 PYs (95%CI = 2.68--4.22). Among all, 72 (12.7%) developed EPTB with an incidence density of 3.36 per 100PYs. Among the remaining 494 patients who did not develop EPTB, 420 were on follow-up, 48 were lost to follow-up, 21 were transferred out and 5 died. The most frequent forms of EPTB were lymph nodes TB (56%, 41) followed equally by pleural TB (15%, 11) and disseminated TB (15%, 11). Other forms were abdominal TB, bone and joint TB, TB of the central nervous system and pericardial TB (**[Fig 2](#pone.0232426.g002){ref-type="fig"}).** Bacteriological, histological and clinical methods were used for the diagnosis of EPTB. Accordingly, nine results were reported positive by bacteriological methods (Culture; 3, Xpert MTB/RIF assay; 6). Fifty-five results were confirmed by histological diagnosis and 16 test results were confirmed based on a combination of clinical and chest radiography. However, different combinations of the above confirmatory methods were used to rule out EPTB.

![Sites of extrapulmonary TB among *HIV* positive patients in Addis Ababa, Ethiopia, from 01 January 2013 up to 31 December 2018 (n = 72).](pone.0232426.g002){#pone.0232426.g002}

Most of EPTB cases (51, 70.83%) occurred within the first year of follow-up. The incidence density was 188/100 PYs, 14.29/100PYs, 11.63/100 PYs, 5.56/100 PYs and 0.41/100 PYs at the end of first, second, third, fourth and fifth years of follow-up respectively **([Table 3](#pone.0232426.t003){ref-type="table"})**. The cumulative probability of EPTB-free survival at the end of, first, two, three, four and five years were 0.91, 0.90, 0.89, 0.88 and 0.87 respectively **([Fig 3](#pone.0232426.g003){ref-type="fig"}).** In terms of survival curves, there were significant variations among baseline WHO stage III or IV and WHO I or II *(P\<0*.*001*), different baseline CD4 counts *(P\<0*.*001*), baseline Hgb value \<10mg/dl and \>10mg/dl *(P\<0*.*001*) and enrolled and not enrolled on HAART (*P\<0*.*001*) **([Fig 4](#pone.0232426.g004){ref-type="fig"}).**

![Kaplan-Meier EPTB free survival curves among *HIV* positive patients in Addis Ababa, Ethiopia, from 01 January 2013 up to 31 December 2018 (n = 566).](pone.0232426.g003){#pone.0232426.g003}

![Kaplan-Meier survival curves of patients with extrapulmonary tuberculosis based on baseline WHO stage (A), baseline CD4 (B) count, baseline anemia (C), IPT intake(D) and enrollment on HAART (E) among *HIV* positive patients in Addis Ababa, Ethiopia, from 01 January 2013 up to 31 December 2018 (n = 566).](pone.0232426.g004){#pone.0232426.g004}

10.1371/journal.pone.0232426.t003

###### Extrapulmonary tuberculosis incidence density among *HIV* positive patients in Addis Ababa, Ethiopia, from 01 January 2013 up to 31 December 2018 (n = 566).

![](pone.0232426.t003){#pone.0232426.t003g}

  Characteristics                  Total   EPTTB   Percent   Person years   EPTB incidence rate(95%CI)
  -------------------------------- ------- ------- --------- -------------- ----------------------------
  **Age group**                                                             
  **15--24**                       38      3       4.17      125.13         2.40(0.78--7.33)
  **25--34**                       230     22      30.56     913.78         2.41(1.59--3.64)
  **35--44**                       205     34      47.22     745.53         4.56(3.28--6.33)
  **\>44**                         93      13      18.06     355.64         3.66(2.14--6.23)
  **Sex**                                                                   
  **Female**                       385     42      58.33     1510.16        2.78(2.06--3.75)
  **Male**                         181     30      41.67     629.92         4.76(3.36--6.75)
  **Marital status**                                                        
  **Single**                       127     16      22.22     483.27         3.31(2.04--5.36)
  **Married**                      260     33      45.83     1012.39        3.26(2.33--4.56)
  **Separated/Divorced**           114     17      23.61     376.68         4.51(2.84--7.18)
  **Widowed**                      65      6       8.33      267.74         2.24(1.02--4.94)
  **Educational status**                                                    
  **No formal education**          100     13      18.06     393            3.31(1.94--5.65)
  **Primary**                      206     24      33.33     772.09         3.117(2.10--4.61)
  **Secondary**                    195     24      33.33     728.32         3.30(2.22--4.88)
  **Tertiary**                     65      11      15.28     246.32         4.47(2.51--7.96)
  **Employment status**                                                     
  **Yes**                          236     26      36.11     929.43         2.80(1.92--4.09)
  **No**                           330     46      63.89     1210.65        3.80(2.86--5.04)
  **Address**                                                               
  **Addis Ababa**                  529     65      90.28     1987.25        3.27(2.58--4.15)
  **Out of Addis Ababa**           37      7       9.72      152.82         4.58(2.22--9.44)
  **Disclosure status**                                                     
  **Yes**                          404     52      72.22     1529.30        3.40(2.60--4.44)
  **No**                           162     20      27.78     610.78         3.27(2.13--5.04)
  **Family size**                                                           
  **1--3**                         334     43      59.72     1271           3.38(2.52--4.54)
  **4--5**                         165     20      27.78     643            3.11(2.02--4.79)
  **\>5**                          67      9       12.50     226            3.98(2.10--7.55)
  **Homeless**                                                              
  **Yes**                          4       1       1.39      11.40          8.77(1.35--57.03)
  **No**                           562     71      98.61     2128.68        3.34(2.65--4.19)
  **Tobacco smoking**                                                       
  **Yes**                          278     32      44.44     1028           3.11(2.21--4.38)
  **No**                           288     40      55.56     1112           3.60(2.65--4.88)
  **Alcohol**                                                               
  **Yes**                          312     39      54.17     1161           3.36(2.47--4.57)
  **No**                           254     33      45.83     979            3.37(2.41--4.71)
  **Taking Khat**                                                           
  **Yes**                          296     34      47.22     1114           3.05(2.19--4.25)
  **No**                           270     38      52.78     1026           3.70(2.71--5.06)
  **Taking hard drugs/Shisha**                                              
  **Yes**                          270     30      41.67     1015           2.96(2.08--4.20)
  **No**                           296     42      58.33     1125           3.73(2.77--5.02)
  **Previous TB history**                                                   
  **Yes**                          53      10      13.89     175.70         5.69(3.12--10.39)
  **No**                           513     62      86.12     1964.37        3.16(2.47--4.03)
  **Baseline functional status**                                            
  **Working**                      488     51      70.83     1966.74        2.59(1.98--3.40)
  **Ambulatory**                   70      19      26.39     162.73         11.66(7.65--17.82)
  **Bedridden**                    8       2       2.78      10.60          18.87(5.41--65.75)
  **Baseline WHO stage**                                                    
  **I/II**                         513     46      63.89     2060.16        2.23(1.68--2.97)
  **III/ IV**                      53      26      36.11     79.92          32.53(23.47--44.61)
  **Baseline CD4 count**                                                    
  **\<50**                         47      20      27.78     96.03          20.83(14.10--30.76)
  **50--200**                      211     34      47.22     723.97         4.70(3.38--6.52)
  **\>200**                        308     18      25.0      1320.08        1.36(0.86--2.16)
  **Baseline Hgb**                                                          
  **\<10g/dl**                     51      18      25.0      94             19.15(12.64--29.01)
  **\>10g/dl**                     515     54      75.0      2046           2.64(2.03--3.43)
  **BMI**                                                                   
  **\<18.5**                       182     33      45.83     532            6.20(4.46--8.63)
  **\>18.5**                       384     39      54.17     1608           2.43(1.78--3.31)
  **On HAART**                                                              
  **Yes**                          476     32      44.44     2056.93        1.56(1.10--2.19)
  **No**                           90      40      55.56     83.15          48.11(38.48--60.14)
  **Initial treatment**                                                     
  **TDF/3TC/NVP**                  14      2       6.25      54             3.70(0.95--14.43)
  **AZT/3TC/NVP**                  56      4       12.50     241            1.66(0.63--4.39)
  **AZT/3TC/EFV**                  39      0       0.00      185            \-
  **TDF/3TC/EFV**                  367     26      81.25     1582           1.64(1.12--2.41)
  **Took IPT Prophylaxis**                                                  
  **Yes**                          252     6       8.33      1206.81        0.50(0.22--1.10)
  **No**                           314     66      91.67     933.27         7.07(5.60--8.92)
  **Took Co-trimoxazole**                                                   
  **Yes**                          476     45      62.50     1988.59        2.26(1.70--3.02)
  **No**                           90      27      37.50     151.48         17.82(12.66--25.06)
  **Co-infection**                                                          
  **Yes**                          265     36      50.0      964.35         3.73(2.71--4.22)
  **No**                           301     36      50.0      1175.73        3.06(2.22--4.22)
  **ART Treatment Interruption**                                            
  **Yes**                          14      1       3.13      53.44          1.87(0.27--13.04)
  **No**                           462     31      96.87     2008.49        1.54(1.09--2.19)
  **ART adherence**                                                         
  **Good**                         459     30      93.75     2007.83        1.49(1.05--2.13)
  **Fair**                         5       0       0         18.18          \-
  **Poor**                         12      2       6.25      35.92          5.57(1.45--21.41)
  **ART regimen change**                                                    
  **Yes**                          8       1       3.13      35.67          2.8(0.41--19.36)
  **No**                           468     31      96.87     2026.27        1.53(1.08--2.17)
  **Follow-up year**                                                        
  **1**                            114     51      70.83     27             \-
  **2**                            19      4       5.56      28             14.29(5.77--35.39)
  **3**                            16      5       6.94      43             11.63(5.10--26.51)
  **4**                            21      4       5.56      72             5.56(2.14--14.40)
  **5**                            396     88      11.1      1970           0.41(3.64--5.48)

EPTB; Extrapulmonary tuberculosis, TB; Tuberculosis, WHO; World Health Organization, Hgb; hemoglobin, BMI; Body Mass Index, HAART; Highly Active Anti-Retroviral Treatment, IPT; Isoniazid Preventive Therapy, ART; Anti-Retroviral Therapy, TDF; Tenofovir, 3TC; Lamivudine, NVP; Nevirapine, AZT; Zidovudine, EFV; Efavirenz, co-infection; the presence of is any comorbidity or infection other than tuberculosis.

Women contributed the highest proportion (42, 58.33%) however the incidence density was higher in males (Males; 4.76/100PY, Women; 2.78/100PY). Among all 72 EPTB cases, 10 (13.89%) had a previous TB treatment history, 21 (29.17%) were either ambulatory or bedridden functional status at enrollment, 26 (36.11%) were either at WHO stage III or IV, 54 (75%) had CD4 count \<200 cells/μl, 18 (25%) had Hgb value \<10 mg/dl, 33 (45.83%) were underweight, 40 (55.56%) did not take ART drugs, 66 (91.67%) did not receive IPT and 27 (37.5%) did not take the CPT **([Table 3](#pone.0232426.t003){ref-type="table"}).**

Predictors of extrapulmonary tuberculosis {#sec020}
-----------------------------------------

In the bi-variable Cox regression analysis, age-group, sex, previous anti-TB treatment, baseline functional status, baseline WHO stage, baseline CD4 count, baseline Hgb value, baseline BMI, HAART status, IPT, and CPT were found as risk factors of the EPTB at a *P-value* of less than 0.25. When all these variables were subjected to multivariable Cox regression analysis, WHO stage III or IV, baseline CD4 count\<50 cells/μl, baseline CD4 count 50--200 cells/μl, baseline Hgb\<10 mg/dl, not on HAART, and not received IPT were found to be the statistically significant independent risk factors (**[Table 4](#pone.0232426.t004){ref-type="table"}).**

10.1371/journal.pone.0232426.t004

###### Bi-variable and multi-variable Cox regression analysis of extrapulmonary tuberculosis among *HIV* positive patients in Addis Ababa, Ethiopia, from 01 January 2013 up to 31 December 2018 (n = 566).

![](pone.0232426.t004){#pone.0232426.t004g}

  Characteristics              Survival status   CHR(95% CI)   AHR(95%CI)                
  ---------------------------- ----------------- ------------- ------------------------- ----------------------
  Age group                                                                              
  15--24                       3                 35            0.598(0.170--2.098)       0.742(0.203--2.704)
  25--34                       22                208           0.660(0.332--1.309)       1.232(0.576--2.638)
  35--44                       34                171           1.1212(0.640--2.296)      1.510(0.771--2.958)
  \>44                         13                80            1                         1
  Sex                                                                                    
  Female                       42                343           1                         1
  Male                         30                151           1.644(1.029--2.627)       0.928(0.555--1.553)
  Previous TB history                                                                    
  Yes                          10                43            1.619(0.830--3.160)       1.437(0.731--2.825)
  No                           62                451           1                         1
  Baseline functional status                                                             
  Working                      51                437           1                         1
  Ambulatory                   19                51            3.684 (2.170--6.254)      0.875(0.480--1.597)
  Bedridden                    2                 6             5.012(1.216--20.668)      0.534(0.108--2.652)
  Baseline WHO stage                                                                     
  I and II                     46                467           1                         1
  III and IV                   26                27            9.997(6.103--16.310)      2.720(1.575--4.697)
  Baseline CD4 count                                                                     
  \<50                         20                27            11.850(6.248--22.474)     4.073(2.064--8.040)
  50--200                      34                177           3.514(1.781--5.588)       2.360(1.314--4.239)
  \>200                        18                290           1                         1
  Baseline Hgb                                                                           
  \<10g/dl                     18                33            4.869(2.839--8.350)       1.979(1.091--3.591)
  \>10g/dl                     54                461           1                         1
  Baseline BMI                                                                           
  \<18.5                       33                149           2.227(1.399--3.544)       1.146(0.680--1.933)
  \>18.5                       39                345           1                         1
  On HAART                                                                               
  Yes                          32                444           1.00                      1
  No                           40                50            19.865 (12.028--32.807)   7.645(4.201--13.263)
  Taken IPT Prophylaxis                                                                  
  Yes                          6                 246           1                         1
  No                           66                248           11.897(5.151--27.479)     4.314(1.769--10.520)
  Taken Co-trimoxazole                                                                   
  Yes                          45                431           1                         1
  No                           27                63            5.926(3.657--9.603)       1.484(0.783--2.814)

CHR; crude hazard ratio, AHR; adjusted hazard ratio, TB; Tuberculosis, WHO; World Health Organization, Hgb; hemoglobin, BMI; Body Mass Index, HAART; Highly Active Anti-Retroviral Treatment, IPT; Isoniazid Preventive Therapy, ART; Anti-Retroviral Therapy, co-infection; the presence of is any comorbidity or infection other than tuberculosis.

Accordingly, PLHIV who were on WHO stage III or IV at the time of enrollment had 2.72 times the risk to develop EPTB at any time compared to those who were on WHO stage I or II (AHR = 2.720, 95%CI = 1.575--4.697). PLHIV who had a baseline CD4 count of \<50 cells/μl and a CD4 count of 50--200 cells/μl were 4.073 times (AHR = 4.073, 95% CI = 2.064--8.040) and 2.36 times (AHR = 2.360, 95%CI = 1.314--4.239) as likely to have EPTB compared to PLHIV who had a baseline CD4 count of \>200 cells/μl respectively. Similarly, PLHIV who had a baseline Hgb value \<10 mg/dl were 1.98 times the risk to develop EPTB at any time compared to PLHIV who had a baseline Hgb value\>10 mg/dl (AHR = 1.979, 95%CI = 1.091--3.591). Also, the risk of developing EPTB among those who did not receive IPT was 4.314 times as high as the risk to develop EPTB among those who took IPT (AHR = 4.314, 95%CI = 1.769--10.520). While, those who took IPT had a 77% reduced risk of EPTB (AHR = 0.232, 95%CI = 0.095--0.565). Similarly, PLHIV who did not enroll on HAART were 7.645 times as likely to develop EPTB compared to those who were on HAART (AHR = 7.645, 95%CI = 4.201--13.263). Such that taking ART drugs reduced the risk of EPTB by 87% (AHR = 0.134, 95%CI = 0.075--0.238) **([Table 4](#pone.0232426.t004){ref-type="table"}).**

Discussion {#sec021}
==========

In the current study, about 12.7% (incidence rate; 3.36/100PYs) of *HIV* positive individuals developed EPTB in their follow-up. Advanced immune suppression at baseline such as an advanced WHO stage, lower CD4 count and anemia were the independent risk factors. However, taking antiretroviral therapy and IPT had a protective benefit.

In the present study, a higher incidence density rate of EPTB was observed among PLHIV. This finding was higher compared to a study done in Northeast Ethiopia \[[@pone.0232426.ref007]\], in Gondar \[[@pone.0232426.ref002]\] and Addis Ababa \[[@pone.0232426.ref003]\]. However, when considering the proportion of EPTB among all *HIV* patients, ours' finding (12.72%) was lower compared to a study done in Addis Ababa \[[@pone.0232426.ref003]\]. In this study, the highest incidence of EPTB was observed in the first year of follow up and decreased in the consecutive years, which were supported by previous studies \[[@pone.0232426.ref002]\] \[[@pone.0232426.ref003], [@pone.0232426.ref007], [@pone.0232426.ref014]\]. The possible explanation could be the late *HIV* diagnosis and might be due to immune reconstitution inflammatory response (IRIS) which is a common phenomenon in *HIV* positive individuals. After starting HAART the level of CD4 count increased that causes pathogen-specific immune responses/inflammation/ which results in enlargement of lymph nodes. As was reported by previous studies done in different countries and settings, \[[@pone.0232426.ref010], [@pone.0232426.ref015]\] \[[@pone.0232426.ref016]--[@pone.0232426.ref019]\], the most frequent forms of EPTB in this study were lymph nodes TB. However, in a study done in Nigeria, the commonest forms of EPTB was abdominal TB \[[@pone.0232426.ref020]\]. The second most frequent forms of EPTB observed in our study were pleural TB and disseminated TB, which were also reported from the current study setting \[[@pone.0232426.ref015]\] and USA \[[@pone.0232426.ref016], [@pone.0232426.ref018]\] The other forms of EPTB such as abdominal TB, bone and joint TB, TB of the central nervous system and pericardial TB observed in the current study were also reported by previous studies \[[@pone.0232426.ref010], [@pone.0232426.ref016]--[@pone.0232426.ref020]\]. Among 72 EPTB cases, only nine were confirmed by bacteriological methods where the diagnosis of EPTB is difficult due to the paucibacillary nature of the disease.

In the current study, those PLHIV who had a previous TB treatment history had a higher incidence of EPTB compared to those not had TB infection history that was also reported before \[[@pone.0232426.ref007], [@pone.0232426.ref021]\]. The baseline functional status of *HIV* patients during enrollment is a key factor for the likely hood of subsequent progression of different diseases \[[@pone.0232426.ref013], [@pone.0232426.ref022]\]. In our study based on the bi-variable analysis, those PLHIV who were on ambulatory at the time of enrollment had a higher risk to develop EPTB compared with those on working functional status (CHR = 3.684, 95%CI = 2.170--6.254). Likewise, this was also observed in bedridden *HIV* positive patients (CHR = 5.012, 95%CI = 1.216--20.668). This might be because *HIV* positive patients who were on ambulatory or bedridden functional status at baseline might have low CD4 counts that could make them more susceptible to co-infections like tuberculosis. Previous studies also supported this \[[@pone.0232426.ref002], [@pone.0232426.ref003], [@pone.0232426.ref007], [@pone.0232426.ref013], [@pone.0232426.ref022], [@pone.0232426.ref023]\]. We observed that the risk to develop EPTB is higher when they are underweight at the baseline, compared to those with normal weight (CHR = 2.227, 95%CI = 1.399--3.544). Similar findings were reported from other studies \[[@pone.0232426.ref006], [@pone.0232426.ref007], [@pone.0232426.ref023]\], where nutritional status is a key factor development of TB.

Based on the multivariable Cox regression analysis, the statistically significant independent predictors of EPTB among PLHIV identified in our study were; WHO stage III or IV, baseline CD4 count \<50 cells/μl, baseline CD4 count 50--200 cells/μl, baseline Hgb \<10 mg/dl, not on HAART and not received IPT prophylaxis. This study revealed that those PLHIV who were in advanced WHO stages III or IV at the time of enrollment had 2.72 times the risk to develop EPTB at any time compared to those who were on WHO stage I or II. Similarly, different studies reported TB was more common in advanced *HIV* stages \[[@pone.0232426.ref002], [@pone.0232426.ref003], [@pone.0232426.ref006], [@pone.0232426.ref007], [@pone.0232426.ref013], [@pone.0232426.ref014], [@pone.0232426.ref020], [@pone.0232426.ref022]--[@pone.0232426.ref029]\].

Immune status is a key factor for the susceptibility of a host for TB, such that when the immune system becomes week the likely hood to be infected with TB increases \[[@pone.0232426.ref006]\] \[[@pone.0232426.ref024]\]. Based on this study and findings from previous studies done in Ethiopia and other countries, individuals who had lower CD4 count at the time of enrollment had higher risk to develop TB \[[@pone.0232426.ref002], [@pone.0232426.ref006], [@pone.0232426.ref014], [@pone.0232426.ref020], [@pone.0232426.ref021], [@pone.0232426.ref023], [@pone.0232426.ref026]--[@pone.0232426.ref033]\]. The other independent predictor of EPTB observed in this study was the baseline hemoglobin value. It is observed that PLHIV who were anemic (Hgb value \<10 mg/dl) had 98% greater risk to develop EPTB compared to PLHIV who were not anemic at the baseline (Hgb value\>10 mg/dl). This was also supported by previous studies \[[@pone.0232426.ref006], [@pone.0232426.ref007], [@pone.0232426.ref022], [@pone.0232426.ref025]\]. Anemia might be indirectly associated with EPTB, where immune compromisation leads to decreased production of red blood cells and EPTB among *HIV* positives.

In the current study, PLHIV who took IPT had a 77% reduced risk of EPTB compared to those who did not take IPT (AHR = 0.232, 95%CI = 0.095--0.565). This finding supported the WHO recommendation; *HIV* patients should receive IPT to decrease the risk of developing TB. This is also recommended in Ethiopia \[[@pone.0232426.ref026]\]. Likewise, a reduced risk of TB among PLHIV who has taken IPT was reported by different scholars \[[@pone.0232426.ref005], [@pone.0232426.ref007], [@pone.0232426.ref022], [@pone.0232426.ref026], [@pone.0232426.ref027], [@pone.0232426.ref029], [@pone.0232426.ref034]--[@pone.0232426.ref037]\]. The other independent predictor of EPTB infection observed in this study was not enrolled on HAART. PLHIV who were on HAART had 87% reduced risk of EPTB compared to those who were not enrolled on HAART (AHR = 0.134, 95%CI = 0.075--0.238). In line with this, other studies also reported the significant decrease risk of EPTB among *HIV* positive individuals who were enrolled on HAART \[[@pone.0232426.ref006], [@pone.0232426.ref022], [@pone.0232426.ref030], [@pone.0232426.ref032]--[@pone.0232426.ref035]\].

Limitation of the study {#sec022}
-----------------------

This study has important limitations as it is a retrospective study of nature. The incomplete records that we excluded from our analysis might introduce selection bias. Besides, we were unable to obtain additional information not captured to the patient\'s chart or registration book. Moreover, the lack of information about the outcomes in the lost and transferred out is another limitation.

Conclusion {#sec023}
==========

Extrapulmonary tuberculosis is the major opportunistic infection among people living with *HIV*. The most frequent forms were lymph nodes TB followed by the equal incidence of pleural TB and disseminated TB. The majority of EPTB cases were occurring in the first years of follow-up. Being on baseline advanced WHO stages, lower baseline CD4 count, and baseline anemia was found to be the statistically significant independent risk factors of EPTB. While taking isoniazid preventive therapy and enrolled on HAART had the protective benefit. Screening of *HIV* positives for extrapulmonary tuberculosis throughout their follow-up would be important.

We acknowledge administrators and staff of St. Paul\'s Hospital Millennium Medical College, Addis Ababa City Administration Health Bureau, Saint Peter Specialized Hospital, *Ras Desta Damtew* hospital, *Arada* Health Center, *Kirkose* Health Center, *Kolfe* Health Center and *Addis Ketema* Health Center for their support and commitment.
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Response to Reviewers

Title: Incidence and Predictors of Extrapulmonary Tuberculosis among People Living with Human Immunodeficiency Virus in Addis Ababa, Ethiopia: A Retrospective Cohort Study.

Editor Comments:

1\. Kindly thoroughly copyedit the manuscript for error using a native speaker

Thank you for the valuable comment. The revised manuscript is reviewed by someone who has better English language skills.

2\. Why is reference 6 in CAPs?

Thank you and we corrected it in the revised manuscript.

3\. Need use to be consistent referencing style. Some references list only 3 while others list 6. Eg Ref 7 and 9

Thank you for the comment, now corrected in the revised manuscript.

4\. Ref 15. Remove typo 15

Thank you and we removed it in the revised manuscript.

Reviewers\' comments

Thank you the reviewers for your valuable suggestions, constructive comments and the clarifications you want.

Reviewer \#1

I read with interest this article. My main comment is that the language needs to be revised.

Thank you. The revised manuscript is reviewed by someone with better English language skill.

Other comments

1\. The authors should provide information on the number of lost to follow up and transferred.

Thank you for the valuable comment, we included in the revised manuscript in line 199-201. "Among the remaining 494 patients who did not develop EPTB, 420 were on follow-up, 48 were lost to follow-up, 21 were transferred out and 5 died".

2\. The authors should also provide information on the modality of diagnosis, in how many was clinical and how many supported by lab/other diagnostic. This also deserves to be included in the discussion since extrapulmonary diagnosis is not easy especially in certain settings

Thank you for the comment, it is described in the revised manuscript in line 2004-2009.

"Bacteriological, histological and clinical methods were used for the diagnosis of EPTB. Accordingly, nine results were reported positive by bacteriological methods (Culture; 3, Xpert MTB/RIF assay; 6). Fifty-five results were confirmed by histological diagnosis and 16 test results were confirmed based on a combination of clinical and chest radiography. However, different combinations of the above confirmatory methods were used to rule out EPTB" We also included in the discussion part in line 268-270.

3\. The authors should provide a limitation section in the discussion, including the lack of information of outcomes in the lost and transferred

Thank you for the comment we included in the revised manuscript in line 312-317.

4\. Conclusions sections. These are not conclusions, but a summary of the results. The authors should provide appropriate conclusion and recommendations.

Thank you for the constructive comments. We corrected accordingly in the abstract section and the conclusion section.

Reviewer \#2:

Methods:

1\. Please clarify the meaning of \"disclosure status\".

Thank you for the comment and we included it in the revised manuscript in line 141-142.

2\. How was addiction to smoking and alcohol defined? Can the authors provide information on smoking status (never vs former vs current), pack-years smoked and quantitative estimate of alcohol consumption? Were these measures associated with EPTB?

Thank you for the comment it is operationalized in line 143. The bi-variable analysis was performed for all variables listed in this study, however only those with a P-Value \<0.25 were subjected to multi-variable analysis.

3\. How was functional status defined/classified?

Thank you for the question we included it in the revised manuscript in line 144.

4\. Were longitudinal CD4 and HIV RNA levels available during follow-up? Were these associated with the outcome?

Thank you for valuable comment. However, we were unable to get enough data to perform analysis because RNA/Viral load/ was started late and, thus no baseline viral load data available. Likewise, CD4 count was available at baseline, but not enough during the follow --up period and at the end of the follow-up period which is replaced by viral load count. In the revised manuscript we included it in the discussion and limitation part.

5\. How many participants had incident PULMONARY TB disease and how was this handled in the analysis? Also, were prevalent pulmonary TB cases excluded?

Thank you for the clarification you want. During the follow-up period, there were 72 patients had incident pulmonary TB without having extrapulmonary TB and were followed until developed extrapulmonary TB or became censored.

6\. Please provide the statistical method used to calculate incidence rate and its 95% confidence interval.

Thank you for the comment and we included it in the revised manuscript in line 159-164. "The EPTB incidence density rate per 100PYs of follow-up in each category is determined by dividing the number of EPTB in each category and multiplying by 100. The 95%CI for the incidence rate is determined using the formula 95%CI= eln incidence rate-Zα/2\*SE, eln incidence rate +Zα/2\*SE"

7\. How was \"IPT completion\" defined?

Thank you for the comment and we included it in the revised manuscript in line 148-149.

8\. Are data on TB infection status available?

Thank you for the question. Previous TB history was assessed and included in the analysis as one risk factor but in the multivariable analysis it was not statistically significant.

9\. How was \"ART interruption\" and \"ART adherence\" defined?

. We included in the revised manuscript under the operational definition section in line 150-154.

10\. Is duration of ART prior to enrollment available? Was this associated with incident EPTB?

Thank you for the question, unfortunately, it is not available.

11\. Did participants who died or were lost to follow-up different from the rest? And was death due to EPTB assessed as an outcome? It may be helpful to consider death and loss-to-follow-up as competing-risks for incident EPTB and analyze these data accordingly.

Thank you for the question and suggestion. "During the follow-up period there were 420 on follow-up, 48 lost to follow-up, 21 transferred out and 5 deaths which are considered as censored. Thus, follow-up data collected from these patients were included in the analysis being pooled as censored. The data collected from lost to follow-up and lost were not different from the rest participants. Death outcome due to EPTB was not assessed in the current study; however, your suggestion is very important".

Results:

1\. How many EPTB cases were defined by clinical vs microbiological diagnosis?

Thank you for the question and we included it in the revised manuscript.

2\. Please report median and inter-quartile range or mean with standard deviation for all continuous exposures.

Thank you for the comment. We presented in the revised manuscript.

3\. Please provide % in Figure-1.

Thank you for the comment and we included it in the revised manuscript.

4\. Table-1 and table-2 may be more informative if stratified by the primary outcome.

Thank you for your suggestion, this is done in table 3.

5\. Is \"tobacco smoking\" in table-1 ever-smoking? Please clarify

Thank you for the question. It is ever smoking and we included in the operational definition.

6\. Please include foot-notes to all tables and figures clarifying abbreviations.

Thank you for the comment and the corrected accordingly in the revised manuscript.

7\. Please clarify what \"co-infection\"means in Table-2.

Thank you for the comment, included in the revised manuscript in the footnote.

8\. Please provide 95% confidence intervals for all incidence rate estimates in the text and tables

Thank you for the comment and we included it in the revised manuscript.

9\. Was alcohol included in uni- and multi-variable analysis?

It is included in the bi-variable analysis and since the P-value was\< 0.25 we did not include in the multivariable analysis.

Discussion:

1\. Can the authors comment on the heterogeneity of HIV populations across the several ART clinics in Ethiopia and comment on the generalizability of their study findings?

Thank you for the suggestion. Even though HIV populations are homogeneous across several ART clinics of Ethiopia, the current study setting is the most populous and congregated city in the country. Thus this may favor TB infection thus generalizing for all HIV populations across the country might be difficult.

2\. It is unclear why IRIS would lead to incident EPTB. Can the authors clarify?

Thank you for the comment. We included it in the revised manuscript in line 260-261.

3\. The conclusion that male sex and not receiving co-trimoxazole prophylaxis are predictors of incident EPTB is incorrect. This may be due to confounding as seen in the uni- and multi-variable regression. Can the authors comment?

Thank you for the comment and we removed it

4\. Can the authors speculate as to why anemia may be associated with incident EPTB?

Thank you for the comment. We speculated in the revised manuscript.

5\. The authors conclude that \"early start of HAART\" and \"early diagnosis of HIV\" should be considered for preventing incident EPTB. This is not supported by the data presented. Can the authors comment on the CD4 cell count at ART initiation (as opposed to enrollment) and whether this as associated with EPTB?

Thank you for the comment. We revised the conclusion.

General:

1\. There are several typos in the manuscript text and figures. Please review and correct.

Thank you for valuable suggestion. We corrected it in the revised manuscript.

2\. Recognizing that English may not be the authors primary language, please consider having this manuscript proof-read for grammatical errors and syntax.

Thank you for the valuable comment. The revised manuscript is reviewed by someone who has better English language skills.
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